Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00600743 · ClinicalTrials.gov registry record · Phase 2
Effect of a CCK-1R Agonist on Food Intake in Humans
A Phase 2 study, sponsored by St. Luke's-Roosevelt Hospital Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00600743: Clinical Trial Phase 2 study, sponsored by St. Luke's-Roosevelt Hospital Center.
NCT00600743 is a Phase 2 study that was terminated before completion, run by St. Luke's-Roosevelt Hospital Center. The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00600743, a Phase 2 study, was terminated before completion, sponsored by St. Luke's-Roosevelt Hospital Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The ultimate aim of this study is to test the hypothesis that the oral cholecystokinin (CCK) agonist GSKI181771X will reduce the size of a binge meal among individuals with Bulimia Nervosa. The study will be conducted in phases. First, an effective dose for reducing food intake, when normal subjects eat normally will be attained. Next, it will be determined whether intake at this dose is reduced in control subjects instructed to eat to capacity. If the dose is still effective compared to placebo, the same dose will be tested in patients with bulimia nervosa.
Primary Outcome
Food Intake at 25-30 min after having drug or placebo under normal and binge eating instructions
Interventions
- DRUG Placebo
- DRUG GSKI181771X (CCK-1R agonist)
- BEHAVIORAL Instructions to binge eat
- BEHAVIORAL Instructions to eat normally
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-01 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Why NCT00600743 stopped before completion
NCT00600743 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00600743 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00600743 about?
NCT00600743 is a clinical study titled "Effect of a CCK-1R Agonist on Food Intake in Humans". The ultimate aim of this study is to test the hypothesis that the oral cholecystokinin (CCK) agonist GSKI181771X will reduce the size of a binge meal among individuals with Bulimia Nervosa. The study will be conducted in phases. First, an effective dose for reducing food intake, when normal subjects...
What is the current status of trial NCT00600743?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2008-01. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00600743?
The interventions under investigation include: Placebo (DRUG), GSKI181771X (CCK-1R agonist) (DRUG), Instructions to binge eat (BEHAVIORAL), Instructions to eat normally (BEHAVIORAL).
Who is sponsoring clinical trial NCT00600743?
This trial is sponsored by St. Luke's-Roosevelt Hospital Center, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00600743's enrollment target sits among peer trials
40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia